Mansfield C, Masaquel A, Sutphin J, Weiss E, Gutierrez M, Wilson J, Boeri M, Li J, Reyes C. Patients' priorities in selecting chronic lymphocytic leukemia treatments. Blood Adv. 2017 Nov 14;1(24):2176-85. doi: 10.1182/bloodadvances.2017007294
Arana A, Huerta C, Prieto D, Montero D, Hermosilla E, Martin E, Mendez L, del Mar Garcia M, Comas M, Giner M, Macia MA, Morros R, Duarte T. Uso de datos basados en historia clinica informatizada ('real world data') en los estudios farmaco-epidemiologicos. Presented at en IDIAP Jordi Gol Conference; October 23, 2017. Barcelona, Spain.
Krueger WS, Anthony MS, Saltus CW, Margulis AV, Rivero-Ferrer E, Monz B, Hirst C, Wormser D, Andrews E. Evaluating the safety of medication exposures during pregnancy: a case study of study designs and data sources in multiple sclerosis. Drugs Real World Outcomes. 2017 Sep;4(3):139-49. doi: 10.1007/s40801-017-0114-9
Kaye JA, Margulis AV, Fortuny J, McQuay LJ, Plana E, Bartsch JL, Bui CL, Perez-Gutthann S, Arana A. Cancer incidence after initiation of antimuscarinic medications for overactive bladder in the United Kingdom: evidence for protopathic bias. Pharmacotherapy. 2017 Jun;37(6):673-83. doi: 10.1002/phar.1932
Wilkinson A, Anderson S, Wheeler SB. Screening for and treating postpartum depression and psychosis: a cost-effectiveness analysis. Matern Child Health J. 2017 Apr;21(4):903-14. doi: 10.1007/s10995-016-2192-9
Earnshaw SR, McDade CL, Chu Y, Fleige LE, Sievenpiper JL. Cost-effectiveness of maintaining daily intake of oat β-glucan for coronary heart disease primary prevention. Clin Ther. 2017 Apr;39(4):804-818.e. doi: 10.1016/j.clinthera.2017.02.012